Ficlatuzumab

N/A

Report date: 2023/10/10 20:05:08

Base Information

Drug NameFiclatuzumab
Drug Alias NameAV-299SCH-900105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatocyte growth factor inhibitors
TargetsHepatocyte growth factor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAveo
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe University Of ArizonaAveo Pharmaceuticals Inc
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterBiodesix Inc
Active IndicationsOropharyngeal NeoplasmsHead and Neck NeoplasmsPancreatic Neoplasms +[8] 
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG